Target- and mechanism-based therapeutics for neurodegenerative diseases: Strength in numbers

Paul C. Trippier, Kristin Jansen Labby, Dustin D. Hawker, Jan J. Mataka, Richard B. Silverman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

120 Scopus citations


The development of new therapeutics for the treatment of neurodegenerative pathophysiologies currently stands at a crossroads. This presents an opportunity to transition future drug discovery efforts to target disease modification, an area in which much still remains unknown. In this Perspective we examine recent progress in the areas of neurodegenerative drug discovery, focusing on some of the most common targets and mechanisms: N-methyl-d-aspartic acid (NMDA) receptors, voltage gated calcium channels (VGCCs), neuronal nitric oxide synthase (nNOS), oxidative stress from reactive oxygen species, and protein aggregation. These represent the key players identified in neurodegeneration and are part of a complex, intertwined signaling cascade. The synergistic delivery of two or more compounds directed against these targets, along with the design of small molecules with multiple modes of action, should be explored in pursuit of more effective clinical treatments for neurodegenerative diseases.

Original languageEnglish (US)
Pages (from-to)3121-3147
Number of pages27
JournalJournal of Medicinal Chemistry
Issue number8
StatePublished - Apr 25 2013

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine


Dive into the research topics of 'Target- and mechanism-based therapeutics for neurodegenerative diseases: Strength in numbers'. Together they form a unique fingerprint.

Cite this